Actinogen Medical Croissance future

Future contrôle des critères 2/6

Les bénéfices de Actinogen Medical devraient diminuer de 22.1% par an tandis que son chiffre d'affaires annuel devrait croître de 20% par an. Le BPA devrait croître de en baisse de 0.01% par an.

Informations clés

-22.1%

Taux de croissance des bénéfices

-0.009%

Taux de croissance du BPA

Biotechs croissance des bénéfices	15.3%
Taux de croissance des recettes	20.0%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	31 Oct 2024

Mises à jour récentes de la croissance future

Pas de mise à jour

Recent updates

Prévisions de croissance des bénéfices et des revenus

CHIA:ACW - Estimations futures des analystes et données financières antérieures (AUD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
6/30/2026	14	-20	-13	N/A	1
6/30/2025	7	-12	-9	N/A	1
6/30/2024	10	-13	-17	-17	N/A
3/31/2024	7	-14	-15	-15	N/A
12/31/2023	5	-15	-13	-13	N/A
9/30/2023	5	-13	-11	-11	N/A
6/30/2023	5	-11	-9	-9	N/A
3/31/2023	5	-11	-9	-9	N/A
12/31/2022	5	-11	-9	-9	N/A
9/30/2022	4	-10	-9	-9	N/A
6/30/2022	4	-9	-10	-10	N/A
3/31/2022	3	-8	-8	-8	N/A
12/31/2021	2	-7	-6	-6	N/A
9/30/2021	2	-6	-4	-4	N/A
6/30/2021	2	-4	-2	-2	N/A
3/31/2021	2	-4	-2	-2	N/A
12/31/2020	3	-4	-2	-2	N/A
9/30/2020	3	-4	-3	-3	N/A
6/30/2020	4	-5	-3	-3	N/A
3/31/2020	5	-6	-5	-5	N/A
12/31/2019	6	-7	-7	-7	N/A
9/30/2019	5	-8	-9	-9	N/A
6/30/2019	5	-10	-10	-10	N/A
3/31/2019	4	-10	-10	-10	N/A
12/31/2018	3	-10	-9	-9	N/A
9/30/2018	3	-8	-8	-8	N/A
6/30/2018	3	-6	-8	-8	N/A
3/31/2018	2	-6	N/A	-6	N/A
12/31/2017	2	-5	N/A	-4	N/A
9/30/2017	1	-4	N/A	-3	N/A
6/30/2017	1	-3	N/A	-1	N/A
3/31/2017	2	-4	N/A	-2	N/A
12/31/2016	3	-4	N/A	-2	N/A
9/30/2016	3	-4	N/A	-4	N/A
6/30/2016	4	-4	N/A	-5	N/A
3/31/2016	3	-5	N/A	-5	N/A
12/31/2015	1	-5	N/A	-5	N/A
9/30/2015	1	-5	N/A	-4	N/A
6/30/2015	0	-5	N/A	-4	N/A
3/31/2015	0	-3	N/A	-2	N/A
12/31/2014	0	-2	N/A	-1	N/A
9/30/2014	0	-1	N/A	-1	N/A
6/30/2014	0	0	N/A	0	N/A
3/31/2014	0	0	N/A	0	N/A
12/31/2013	0	0	N/A	0	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: ACW devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: ACW devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: ACW devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de ACW ( 20% par an) devrait croître plus rapidement que le marché Australian ( 5.7% par an).

Croissance élevée des revenus: Le chiffre d'affaires de ACW ( 20% par an) devrait croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de ACW devrait être élevé dans 3 ans

Actinogen Medical Croissance future

Future contrôle des critères 2/6

Informations clés

Mises à jour récentes de la croissance future

Recent updates

Actinogen Medical Appoints Andrew Udell as Chief Commercial Officer

Actinogen Medical Limited has completed a Follow-on Equity Offering in the amount of AUD 3 million.

Actinogen Medical Limited, Annual General Meeting, Nov 14, 2024

New major risk - Revenue and earnings growth

Actinogen Medical Limited Announces Further Positive Results on Depression in the XanCIDD Phase 2A Trial

Actinogen Medical Limited as Announces Achievement of Clinically and Statically Significant Superiority of Xanamem over Placebo on Depression in Xanacidd Phase 2A Trial

New minor risk - Market cap size

Actinogen Medical Limited Announces the Peer-Reviewed Publication of its Phase 2a Biomarker

New major risk - Revenue and earnings growth

Actinogen Medical Limited has filed a Follow-on Equity Offering in the amount of AUD 5 million.

Actinogen Medical Limited Announces First Patient Treated in XanaMIA Phase 2b Alzheimer's Disease Trial

Actinogen Medical Limited Announces Enrolment in the XanaCIDD Phase 2A Proof-Of-Concept Trial

Actinogen Medical Limited Announces CFO Changes

AActinogen Medical Limited to Present Progress on Phase 2 Trials At the Bio Investor Forum, San Francisco and Clinical Trials on Alzheimer's Disease Conference, Boston

Actinogen Medical Limited Announces Optimization of XanaMIA Phase 2b Trial in Patients with Mild-to-Moderate Alzheimer's Disease to Reduce Cost and Time to Initial Results

New minor risk - Shareholder dilution

Actinogen Medical Limited, Annual General Meeting, Nov 08, 2023

New minor risk - Financial data availability

New major risk - Financial position

Actinogen Medical Limited to Present Progress on Cognitive Impairment in Depression and Alzheimer's Disease Phase 2 Trials at the BIO International Convention

Actinogen Medical Limited Announces Executive Changes

Actinogen Medical Ltd Announces Receipt of Agreement from US Food and Drug Administration Agrees to Six-Month Phase 2b Alzheimers Disease Trial

Actinogen Medical Limited Announces First Patient Treated in Depression and Cognitive Impairment Phase 2 Clinical Trial

Actinogen Medical Limited Announces First Patient Treated in XanaCIDD Phase 2 Depression Trial

MD, CEO & Director recently bought AU$94k worth of stock

Actinogen Medical Limited Announces Positive Alzheimers Disease Clinical Results

Actinogen Medical Limited, Annual General Meeting, Nov 16, 2022

Actinogen Medical Limited Announces Phase 2 Trials in Alzheimer's Disease and Depression

Actinogen Medical Limited Announces Phase 2 Trial Designs for AD & MDD

MD, CEO & Director recently bought AU$128k worth of stock

Actinogen Medical Limited Announces Positive XanaMIA Results for Xanamem

Actinogen Medical Limited Announces Executive Changes

Actinogen Medical Expects Top-Line Results for the XanaMIA Part A Trial to Be Available in April 1

Actinogen Medical Announces Enrolment Reach in the XanaMIA Part A Trial of 105 Participants

Actinogen Medical Limited Completes Global Patent Family Grant

Actinogen Medical Limited Announces First Patient Enrolled in XanaMIA Trial

Actinogen Receives Positive Pre-IND FDA Advice for FXS

Actinogen Medical Receives Ethics Committee Approval for XanaMIA study

Actinogen Medical Limited Appoints Steven Gourlay as CEO

Actinogen Medical Limited Announces Executive Changes

Actinogen Medical Wins FDA Actinogen's Drug Xanamem Rare Paediatric Disease Designation for the Treatment of Fragile X Syndrome

Actinogen Medical Limited Announces Two New Clinical Trials

Actinogen Medical Limited Appoints Jeff Carter as Chief Financial Officer

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance